Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study

Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study Publisher Pubmed

Soltanzadeh S¹ ; Saeedian A¹ ; Ghalehtaki R¹ ; Ayati M² ; Nowroozi M² ; Haddad P¹ ; Sabet MS³ ; Kheirolahi A⁴

Show Affiliations

1. Department of Radiation Oncology, Tehran University of Medical Sciences, School of Medicine, Tehran, Iran
2. Department of Urology, Tehran University of Medical Sciences, School of Medicine, Tehran, Iran
3. Department of Radiation Oncology, Iran University of Medical Sciences, School of Medicine, Tehran, Iran
4. Department of psychiatry, Iran University of Medical Sciences, School of Medicine, Tehran, Iran

Source: Clinical Genitourinary Cancer Published:2023

Abstract

Purpose: To evaluate the feasibility, tolerance and efficacy of cisplatin+capecitabine as a proposed combination in concurrent chemoradiotherapy for patients with muscle-invasive bladder cancer (MIBC). Methods: MIBC patients with stage T2-T4aN0M0 participated in this single-arm clinical trial. After maximal TURBT, 66Gy/33 daily fractions of radiation were administered with concurrent chemotherapy of cisplatin (35 mg/m2) and capecitabine (625 mg/m2). The primary endpoint was treatment tolerability, defined as receiving capecitabine+cisplatin combination for at least 5 weeks during radiation therapy. The secondary endpoints included complete response (CR) and acute toxicity rates. Results: This study included 19 MIBC patients from 2018 to 2019. Eighteen patients (94.7%, 95%CI: 75.4-99.0) completed the planned treatment course. Only one patient (5.26%, 95%CI: 0.9-24.6) discontinued the treatment due to grade-3 GI toxicity. Among those who completed the treatment, CR was seen in 12 patients (66.7%, 95% CI = 44.4-88.9) with no grade ≥ 3 toxicities. The most common grade-2 side effects during therapy were renal complications (57.9%), and the only grade-2 complication after therapy was urinary-related (11.1%). The median follow-up was 31 months and the median overall survival (OS) was 31 months. The 2-year OS was 78% (95% CI 58.4-97.6), Cystectomy-free survival was 61% (95% CI: 37.5-84.5), and the median OS after recurrence was 13 months. Distant metastases were the first type of recurrence in most patients with a recurrence, which occurred in 7 (36.8%) patients. Median metastasis-free survival (MFS) was 30 months, and 2-year MFS was 66% (95% CI:45-87). Conclusion: The promising tolerability rate seen with concurrent cisplatin+capecitabine in this study was comparable to the available literature. Thus, this combination concurrently with radiation warrants further studies in the context of chemoradiotherapy of MIBC. © 2022 Elsevier Inc.

Style	Citing Format
MLA	Soltanzadeh S, et al.. "Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study." Clinical Genitourinary Cancer, vol. 21, no. 1, 2023, pp. 105.e1-105.e6.
APA	Soltanzadeh S, Saeedian A, Ghalehtaki R, Ayati M, Nowroozi M, Haddad P, Sabet MS, Kheirolahi A (2023). Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study. Clinical Genitourinary Cancer, 21(1), 105.e1-105.e6.
Chicago	Soltanzadeh S, Saeedian A, Ghalehtaki R, Ayati M, Nowroozi M, Haddad P, Sabet MS, Kheirolahi A. "Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study." Clinical Genitourinary Cancer 21, no. 1 (2023): 105.e1-105.e6.
Harvard	Soltanzadeh S et al. (2023) 'Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study', Clinical Genitourinary Cancer, 21(1), pp. 105.e1-105.e6.
Vancouver	Soltanzadeh S, Saeedian A, Ghalehtaki R, Ayati M, Nowroozi M, Haddad P, et al.. Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study. Clinical Genitourinary Cancer. 2023;21(1):105.e1-105.e6.
BibTex	@article{ author = {Soltanzadeh S and Saeedian A and Ghalehtaki R and Ayati M and Nowroozi M and Haddad P and Sabet MS and Kheirolahi A}, title = {Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study}, journal = {Clinical Genitourinary Cancer}, volume = {21}, number = {1}, pages = {105.e1-105.e6}, year = {2023} }
RIS	TY - JOUR AU - Soltanzadeh S AU - Saeedian A AU - Ghalehtaki R AU - Ayati M AU - Nowroozi M AU - Haddad P AU - Sabet MS AU - Kheirolahi A TI - Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; a Single Arm Study JO - Clinical Genitourinary Cancer VL - 21 IS - 1 SP - 105.e1 EP - 105.e6 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract